Skip to main content

Table 1 Patient characteristics N = 14

From: Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Variable

N (%)

Gender, n (%)

 

Male

6 (42.8)

Female

8 (57.2)

Age

 

Median, years (range)

63 (37–79)

ECOG PS, n (%)

 

0

4 (28.6)

1

10 (71.4)

Histological subtype (%)​

 

Leiomyosarcomas

6 (42.8)

Angiosarcomas

2 (14.4)

Other histotypes*

6 (42.8)

Grade (%)

 

2

5 (35.7)

3

1 (7.1)

Unknow

8 (57.1)

Stage, n (%)

 

Locally advanced

1 (7.1)

Metastatic

13 (92.9)

Prior lines of chemotherapy, n (%)​

 

1​

5 (35.7)

2​

1 (7.1)

> 2​

8 (57.1)

  1. *Epithelioid sarcoma n = 1, Dedifferentiated liposarcoma n = 1, myxoid liposarcoma : n = 1, endometrial stroma sarcoma n = 1, low grade fibromyxoid sarcoma n = 1, Undifferentiated pleomorphic sarcoma n = 1